MedTrace Logo

Early FDG PET in Melanoma

NCT02716077 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-07-23

No results posted yet for this study

Summary

Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.

Conditions

  • Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma

Interventions

RADIATION

FDG PET/CT imaging

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Michael Farwell, MD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NA
Purpose
OTHER
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02716077 on ClinicalTrials.gov